Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: DR. BOND who wrote (2711)	11/20/1997 2:14:00 PM
From: Linda Kaplan	Read Replies (1) \| Respond to of 23519

Very nice article. Thanks. Nice to see VVUS over 25 again, but shooting for 45 this year. hehe Linda

To: DR. BOND who wrote (2711)	11/20/1997 3:31:00 PM
From: Sal Milani	Read Replies (1) \| Respond to of 23519

To all: I sent the following to the Wall Street Journal: >>Re: WSJ 11/18/97 "Schering-Plough Enters License Accord With Zonagen for Anti-Impotence Drug", by Robert Langreth As a shareholder in Vivus, I was disappointed that you did not mention the MUSE treatment for male impotency. You mentioned "existing therapies are cumbersome, typically involving injections into the penis." MUSE is not an injection. It uses a tiny suppository which is inserted in the urethra. In Vivus's first nine months of production it's sales were over $100 million and it is expanding production capacity several fold to keep up with demand. It seems that it should have at least been mentioned in your report.<<